FindMyKOL
Clinical trialNCT07650266Not, yet, recruitingPhase 1Interventional

A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma

SponsorMemorial Sloan Kettering Cancer CenterEnrollment60Nasopharyngeal CancerNasopharyngeal CarcinomaNasopharynx CancerNasopharynx Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin before standard chemoradiation.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Memorial Sloan Kettering Basking Ridge (limited Protocol Activities)

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Monmouth (limited Protocol Activities)

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Bergen (limited Protocol Activities )

    Montvale, New Jersey, United States

  • Memorial Sloan Kettering Suffolk- Commack (limited Protocol Activities)

    Commack, New York, United States

  • Memorial Sloan Kettering Westchester (limited Protocol Activities)

    Harrison, New York, United States

  • Memorial Sloan Kettering Cancer Center (all Protocol Activities)

    New York, New York, United States

  • Memorial Sloan Kettering at Nassau (limited Protocol Activities)

    Uniondale, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cemiplimab →Fianlimab
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Sept 2026
Primary completion
31 Jul 2030
Completion
31 Jul 2030
Last update posted
11 Aug 2026
Registered enrollment
60
Registry id
NCT07650266
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.